Dated: February 15, 1989.

Don M. Newman,

Acting Secretary.

[FR Doc. 89-4418 Filed 2-24-89; 8:45 am]

BILLING CODE 4110-60-M

Alcohol, Drug Abuse, and Mental Health Administration

Substance Abuse Prevention Conference Grant

AGENCY: Office for Substance Abuse Prevention, ADAMHA, HHS.

ACTION: Program Announcement Notice AD-89-A.

Introduction and Backround

The Office for Substance Abuse Prevention (OSAP) announces a program to support domestic conferences for the purpose of coordinating, exchanging, and disseminating information in furtherance of OSAP's mission to prevent alcohol and other drug abuse. This support is provided under section 508 of the Public Health Service Act. Applications are invited for conferences relating to substance abuse prevention, including conferences for the purposes of information dissemination to the services community and the general public, and national strategy development for substance abuse prevention.

The intended audiences for this announcement are principally the consumer and services-oriented constituency groups—including those representing State and local governments, professional associations, voluntary organizations and self-help groups which share mutual interests with OSAP relating to community consensus building, leadership, and advocacy of our national goals.

Program Goals

OSAP will assist in supporting planned meetings and conferences sponsored by new or ongoing constituent organizations or coalitions in their efforts to prevent alcohol and other drug abuse. Priority consideration will be given to applications which demonstrate the potential for knowledge dissemination, interface with health promotion concepts and practices, resource utilization and/or consensus building in furtherance of the OSAP mission of combating alcohol and other drug abuse.

Definitions

The following definitions apply to this grant program:

1. *Conference* [1]—a symposium, seminar, workshop, or any other organized and formal meeting lasting one or more days where persons assemble to exchange information and address information or strategy development needs in such areas as sharing new technologies, problem-solving, network-building or public policy deliberations.

2. *Eligible Grantee*—all public and private, profit and not for profit entities may apply. An individual is not eligible to receive grant support for a conference.

Period of Support

Awards will be made for a maximum of 12 months and most frequently will be for shorter periods.

Availability of Funds

For FY 1989, it is estimated that approximately $1,000,000 will be available for constituencies-initiated conferences. It is expected that awards will be limited to no more than $50,000 for any one conference. OSAP may fund in whole or in part any or all of the applications submitted based upon the results of application review.

Application Procedure

Application materials (PHS 398; rev. 9/86 and PHS 5161-1; rev. 4/88) are available from:

National Clearinghouse for Alcohol and Drug Information (NCADI), P.O. Box 2345, Rockville, Maryland 20852, Telephone: (301) 468-2600.

State and local governments should use Form PHS 5161-1. The title of this Announcement, "Substance Abuse Prevention Conference Grant", AD 89-A, should be typed in item 9 on the face page of the PHS 5161-1. Other applicants should use Form PHS 398 and identify the title and number of the announcement in item 2.

Applicants should return the signed original and two permanent, legible copies (if using form PHS 5161-1) or six copies (if using form PHS 398) to:

OSAP Programs, Division of Research Grants, National Institutes of Health, 5333 Westbard Avenue, Bethesda, Maryland 20892.

IMPORTANT—The mailing envelope (including that provided by an express carrier) must be clearly marked "OSAP Conference Grant Program"

It is requested that those applicants submitting for the May 15, 1989 deadline, an additional copy of the application be sent directly to:

Dr. Salvatore Cianci, Associate Director for Program Coordination and Review, Office for Substance Abuse Prevention, ADAMHA, c/o NCADI, P.O. Box 2345, Rockville, Maryland 20852.

Applications submitted in response to this announcement are subject to the intergovernmental review requirements of Executive Order 12372, "Intergovernmental Review of Federal Programs," as implemented through Department of Health and Human Services Regulations at 45 CFR Part 100. Through this process, States, in consultation with local governments, are provided the opportunity to review and comment on applications for Federal financial assistance. Applicants should contact the State's Single Point of Contact (SPOC) as early as possible to determine the applicable procedure. A current listing of SPOCs will be enclosed with the application kit. Applicants should note that comments received from the State will be considered as a factor in the review of their applications. SPOC comments should be sent to the Executive Secretary, Initial Review Group no later than 60 days after the relevant receipt date. Applicants will be informed as to the Executive Secretary's name and address after receipt of the application.

Application Characteristics

The narrative section should be written in a manner that is self-explanatory to outside reviewers unfamiliar with prior related activities of the applicant. It must be well-organized and contain the information necessary for reviewers to understand the project. Sections A-E may not exceed a total length of 10 single spaced pages. Applications exceeding these page limits for the narrative section will not be accepted for review. The page limit will be rigorously enforced. Returned applications will be eligible for resubmission, after appropriate revisions, at the next application receipt date. Appendices may be attached for specialized materials but should not be used merely to extend the narrative.

Abstract—This should precede the body of the narrative, be single spaced and not exceed 30 lines. Included in the abstract should be:

- The title of the conference;
- Location of the conference
- Inclusive dates of the conference;
- Expected number of registrants and type of audience.
- Major purpose of the conference.

[1] Conferences supported by this program are *not* intended to synthesize or disseminate research information for the scientific research community.

Index Page—Immediately following the abstract page the applicant will be required to provide an index page identifying the page where each section of the outline begins.

The following sections A–E replace the general insturctions for completing Part II (research plan) of the application form 398 or Part IV (program narrative) of the application form PHS 5161–1:

A. *Specific Aims*

Specific objectives of the conference, including the target audience and any developments it may stimulate;

B. *Background and Significance*

Justification of the conference, including potential national or regional significance for the field of substance abuse, the problems it intends to clarify and the developments it may stimulate; Information about all related conferences held on this subject during the last three years (if known) and a description of how the conference will relate to these past relevant activities;

C. *Approach/Method*

Conference format and proposed agenda, including list of principal areas or topics to be addressed, names of key participants with their credentials, and the basis for selection of topics and participants.

D. *Project Management Plan*

Composition and role of the organizing or planning committee, including brief biographical sketches of individuals responsible for planning the conference;

E. *Resources*

Using the budget pages of form PHS 398 or form PHS 5161–1, applicant should present the budget requested from OSAP in each of the following five categories. Support requested from OSAP may not exceed $50,000.

- Personnel—Itemize and prorate salary for professional and non-professional staff for the amount of time spent on the meeting.
- *Equipment*—Itemize rental costs, projection, PA systems, exhibits, phones, etc.
- *Supplies*—Itemize stationary, mailings, telegraph, etc.
- *Travel*—Itemize travel costs for staff, speakers, participants; itemize per diem or actual charges for staff and participants, specify number of days and number of people.
- *All Other Expenses*—Itemize costs for: printing programs, notices, badges, signs, etc.; registration fees, rental of conference space, recording and editorial services, and translation and report costs.

In addition, in section E, identify other sources of support for this conference and indicated the planned budget categories, if known.

Review Process

Applications submitted in response to this program announcement will be reviewed in accordance with ADAMHA peer review procedures for grants. Applicants should be sure to submit completed applications. OSAP staff will screen applications upon receipt and return those that are judged to be incomplete, non-responsive to this announcement or non-conforming (e.g., exceed the page limits). Returned applications will *not* be accepted for this review schedule but may be submitted for the next receipt/review cycle, if the review and conference schedules are compatible. Applications judged to be conforming, responsive, and competitive will be reviewed for technical merit in accord with the PHS and ADAMHA policies for peer review. The review group(s) (IRG) will be composed primarily of non-Federal experts. Notification of the review outcome will be sent to the applicant upon completion of the initial review. In addition, the recommendations of the technical merit review groups may be submitted for information and additional consultation to an OSAP Advisory Board.

Applicants submitting applications for the first receipt date who are unsuccessful in receiving funding may submit a revised application for scheduled future receipt dates, if that schedule is compatible with the planned conference.

Review Criteria

Criteria for review of applications will include the following:

- Potential regional or national significance of the conference for the field of alcohol and drug abuse prevention;
- Clarity and justification of overall objectives, aims, and goals of the conference:
- Manner in which the conference is planned and organized, presence of an administrative and organizational structure that will facilitate attainment of the proposed objective(s) of the conference;
- Qualifications and experience of project staff, principal director, and other key personnel;
- Participation of appropriate speakers or presenters;
- Adequacy of proposed facilities and resources;
- Appropriateness of the budget, staffing plan, and time frame to complete the conference.

Award Criteria

Applications will be considered for funding on the basis of overall technical merit of the project as determined by the review process. Other criteria will include:

- Program balance and relevance to the areas of alcohol and other drug abuse prevention.
- Availability of funds.

Terms and Conditions of Support

Assistance will be provided in the form of a discretionary grant. Grant funds may be used only for those expenses clearly related to and necessary to carry out the approved conference activities. Indirect costs are *not* allowed under this program. It should also be noted that *no profit or fee* will be provided to for-profit organizations.

Grants must be administered in conformance with the *Public Health Service Grants Policy Statement* (Rev. January 1, 1987), which is available for $4.50 from the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402. When ordering copies, the GPO stock number, GPO 017–020–00092–7, should be referenced.

OSAP Application Receipt and Review Schedule

For Initial Receipt, Receipt Date
May 15,1989
IRG Review
July 15, 1989
Earliest Start Date
September, 1989

Subsequent Receipt and Review Schedule (This schedule is subject to change in accordance with program priorities)

Receipt Date
November 15, 1989
April 15, 1990
IRG Review
February, 1989
July, 1990
Earliest Start Date
April, 1989
September, 1990

Applications received after the above receipt dates are subject to assignment to the next review cycle or may be returned to the applicant.

Reporting Requirements

Grantees are responsible for submitting the following reports to the Office for Finance, Policy, and Planning, OSAP within 90 days after upon completion or termination of a grant in support of a conference:

A final progress report which should include:

a. The grant number;

b. The title, date, and place of the conference;

c. The name of the person shown on the application as the conference director or program director;

d. Name(s) of the organization(s) that conducted the conference;

e. List of the individuals who participated as speakers or discussants in the formally planned sessions of the meeting and their organizational affiliations;

f. Copies of papers/speeches presented at the conference;

g. A summary of the conference proceedings.

Publications resulting from the meeting must also be submitted when available.

• A final status (expenditure) report. Records of expenditures must be maintained in accordance with the provisions of 45 CFR Part 74, Subpart D.

Contacts for Additional Information

Office for Finance, Planning, and Evaluation, Room 9–A–54, 5600 Fishers Lane, Rockville, Maryland 20857, (301) 443–0365.

The Catalog of Federal Domestic Assistance number for this program is 13.174.

Joseph R. Leone,

Associate Administrator for Management, Alcohol, Drug Abuse, and Mental Health Administration.

[FR Doc. 89–4412 Filed 2–24–89; 8:45 am]

BILLING CODE 4160–20–M

Food and Drug Administration

[Docket No. 89F–0038]

American Cyanamid Co.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a food additive petition has been filed by American Cyanamid Co. proposing that the food additive regulations be amended to provide for the safe use of sulfosuccinic acid 4-ester with polyethylene glycol dodecyl ether, disodium salt, as an emulsifier in polyvinyl acetate, acrylic, and vinyl/acrylic polymers for food-contact coatings.

FOR FURTHER INFORMATION CONTACT: Marvin D. Mack, Center for Food Safety and Applied Nutrition (HFF–334), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–472–5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 9B4120) has been filed by American Cyanamid Co., One Cyanamid Plaza, Wayne, NJ 07470, proposing that § 178.3400 *Emulsifiers and/or surface-active agents* (21 CFR 178.3400) be amended to provide for the safe use of sulfosuccinic acid 4-ester with polyethylene glycol dodecyl ether, disodium salt, as an emulsifier in polyvinyl acetate, acrylic, and vinyl/acrylic polymers for food-contact coatings.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: February 17, 1989.

Richard J. Ronk,

Acting Director, Center for Food Safety, and Applied Nutrition.

[FR Doc. 89–4414 Filed 2–24–89; 8:45 am]

BILLING CODE 4160–01–M

[Docket No. 89N–0062]

Drug Export; Ibuprofen Caplets, 200 MG. (Capsule Shaped Tablet)

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Par Pharmaceutical, Inc., has filed an application requesting approval for the export of the human drug *Ibuprofen Caplets*, 200 MG. (Capsule Shaped Tablet) to Canada.

ADDRESS: Relevant information on this application may be directed to the Dockets Management Branch (HFA–305), Food and Drug Administration, Rm. 4–62, 5600 Fishers Lane, Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human drugs under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: Rudolf Apodaca, Division of Drug Labeling Compliance (HFD–310), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–295–8063.

SUPPLEMENTARY INFORMATION: The Drug Export Amendments Act of 1986 (Pub. L. 99–660) (section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382)) provides that FDA may approve applications for the export of drugs that are not currently approved in the United States. The approval process is governed by section 802(b) of the act. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the **Federal Register** within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that Par Pharmaceutical, Inc., One Ram Ridge Rd., Spring Valley, NY 10977, has filed an application requesting approval for the export of the drug *Ibuprofen Caplets*, 200 MG. (Capsule Shaped Tablet), to Canada. This product is used for the temporary relief of minor aches and pains associated with the common cold, headache, toothache, muscular aches, backache, for the minor pain of arthritis, for the pain of menstrual cramps, and for reduction of fever. The application was received and filed in the Center for Drug Evaluation and Research on February 13, 1989, which shall be considered the filing date for purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch (address above) in two copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. These submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

The agency encourages any person who submits relevant information on the application to do so by March 9, 1989, and to provide an additional copy of the submission directly to the contact person identified above, to facilitate consideration of the information during the 30-day review period.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 802, Pub. L. 99–660 (21 U.S.C. 382)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Drug Evaluation and Research (21 CFR 5.44).

Dated: February 16, 1989.

Daniel L. Michels,

Director, Office of Compliance, Center for Drug Evaluation and Research.

[FR Doc. 89-4453 Filed 2-24-89; 8:45 am]

BILLING CODE 4160-01-M

Advisory Committees; Meetings

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: This notice announces forthcoming meetings of public advisory committees of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meetings and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

Meetings: The following advisory committee meetings are announced:

Gastrointestinal Drugs Advisory Committee

Date, time, and place. March 15 and 16, 1989, 9 a.m., Conference Rms. D and E, Parklawn Bldg., 5600 Fishers Lane, Rockville, MD.

Type of meeting and contact person. Open public hearing, March 15, 1989, 9 a.m. to 10 a.m., unless public participation does not last that long; open committee discussion, 10 a.m. to 5 p.m.; open committee discussion, March 16, 1989, 9 a.m. to 2 p.m.; closed committee deliberations, 2 p.m. to 4 p.m.; Joan C. Standaert, Center for Drug Evaluation and Research (HFD-180), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-0479 or 419-259-6211.

General function of the committee. The committee reviews and evaluates available data on the safety and effectiveness of marketed and investigational new drugs for use in the treatment of gastrointestinal and blood coagulation disorders and diseases and makes recommendations regarding the appropriate clinical development of such products.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person as soon as possible.

Open committee discussion. On March 15, 1989, the committee will discuss Losec (omeprazole), new drug application (NDA) 19-810, Merck & Co., to be indicated for acute duodenal ulcer, gastroesophageal reflux disease, Zollinger-Ellison syndrome, and other hypersecretory conditions; and on March 16, 1989, the committee will discuss Motilium® (domperidone), NDA 19-472, Janssen Pharmaceutica, Inc., to be indicated for diabetic gastroparesis.

Closed committee deliberations. The committee will discuss trade secret or confidential commercial information relevant to pending and future applications for a drug intended for gastrointestinal use. This portion of the meeting will be closed to permit discussion of this material (5 U.S.C. 552b(c)(4)).

Blood Products Advisory Committee

Date, time, and place. March 23, 1989, 9 a.m., Jack Masur Auditorium, Varren Grant Magnuson Clinical Center, Bldg. 10, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD.

Type of meeting and contact person. Open public hearing, 9 a.m. to 10 a.m., unless public participation does not last that long; open committee discussion, 10 a.m. to 11:30 a.m.; closed committee deliberations, 12:30 p.m. to 1:30 p.m.; open committee discussion, 1:30 p.m. to 2:30 p.m.; Linda A. Smallwood, Center for Biologics Evaluation and Research (HFB-400), Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892, 301-496-4396.

General function of the committee. The committee reviews and evaluates available data on the safety, effectiveness, and appropriate use of blood products intended for use in the diagnosis, prevention, or treatment of human diseases.

Agenda—Open public hearing. Interested persons requesting to present data, information, or views, orally or in writing, on issues pending before the committee should notify the committee contact person.

Open committee discussion. The committee will discuss the approvability of the Abbott HIV Antigen EIA test.

Closed committee deliberations. The committee will discuss trade secret or confidential commercial information relevant to the pending biological product license application. This portion of the meeting will be closed to permit discussion of this information (5 U.S.C. 552b(c)(4)).

Each public advisory committee meeting listed above may have as many as four separable portions: (1) An open public hearing, (2) an open committee discussion, (3) a closed presentation of data, and (4) a closed committee deliberation. Every advisory committee meeting shall have an open public hearing portion. Whether or not it also includes any of the other three portions will depend upon the specific meeting involved. The dates and times reserved for the separate portions of each committee meeting are listed above.

The open public hearing portion of each meeting shall be at least 1 hour long unless public participation does not last that long. It is emphasized, however, that the 1 hour time limit for an open public hearing represents a minimum rather than a maximum time for public participation, and an open public hearing may last for whatever longer period the committee chairperson determines will facilitate the committee's work.

Public hearings are subject to FDA's guideline (Subpart C of 21 CFR Part 10) concerning the policy and procedures for electronic media coverage of FDA's public administrative proceedings, including hearings before public advisory committees under 21 CFR Part 14. Under 21 CFR 10.205, representatives of the electronic media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA's public administrative proceedings, including presentations by participants.

Meetings of advisory committees shall be conducted, insofar as is practical, in accordance with the agenda published in this **Federal Register** notice. Changes in the agenda will be announced at the beginning of the open portion of a meeting.

Any interested person who wishes to be assured of the right to make an oral presentation at the open public hearing portion of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person attending the hearing who does not in advance of the meeting request an opportunity to speak will be allowed to make an oral presentation at the hearing's conclusion, if time permits, at the chairperson's discretion.

Persons interested in specific agenda items to be discussed in open session may ascertain from the contact person the approximate time of discussion.

Details on the agenda, questions to be addressed by the committee, and a current list of committee members are available from the contact person before and after the meeting. Transcripts of the open portion of the meeting will be available from the Freedom of Information Office (HFI-35), Food and Drug Administration, Room 12A-16, 5600 Fishers Lane, Rockville, MD 20857, approximately 15 working days after the meeting, at a cost of 10 cents per page. The transcript may be viewed at the Dockets Management Branch (HFA-305), Food and Drug Administration, Room 4-62, 5600 Fishers Lane, Rockville, MD 20857,

approximately 15 working days after the meeting, between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary minutes of the open portion of the meeting will be available from the Freedom of Information Office (address above) beginning approximately 90 days after the meeting.

The Commissioner, with the concurrence of the Chief Counsel, has determined for the reasons stated that those portions of the advisory committee meetings so designated in this notice shall be closed. The Federal Advisory Committee Act (FACA), as amended by the Government in the Sunshine Act (Pub. L. 94–409), permits such closed advisory committee meetings in certain circumstances. Those portions of a meeting designated as closed, however, shall be closed for the shortest possible time, consistent with the intent of the cited statutes.

The FACA, as amended, provides that a portion of a meeting may be closed where the matter for discussion involves a trade secret; commercial or financial information that is privileged or confidential; information of a personal nature, disclosure of which would be a clearly unwarranted invasion of personal privacy; investigatory files compiled for law enforcement purposes; information the premature disclosure of which would be likely to significantly frustrate implementation of a proposed agency action; and information in certain other instances not generally relevant to FDA matters.

Examples of portions of FDA advisory committee meetings that ordinarily may be closed, where necessary and in accordance with FACA criteria, include the review, discussion, and evaluation of drafts of regulations or guidelines or similar preexisting internal agency documents, but only if their premature disclosure is likely to significantly frustrate implementation of proposed agency action; review of trade secrets and confidential commercial or financial information submitted to the agency; consideration of matters involving investigatory files compiled for law enforcement purposes; and review of matters, such as personnel records or individual patient records, where disclosure would constitute a clearly unwarranted invasion of personal privacy.

Examples of portions of FDA advisory committee meetings that ordinarily shall not be closed include the review, discussion, and evaluation of general preclinical and clinical test protocols and procedures for a class of drugs or devices; consideration of labeling requirements for a class of marketed drugs or devices; review of data and information on specific investigational or marketed drugs and devices that have previously been made public; presentation of any other data or information that is not exempt from public disclosure pursuant to the FACA, as amended; and, notably deliberative sessions to formulate advice and recommendations to the agency on matters that do not independently justify closing.

This notice is issued under sections 10(a) (1) and (2) of the Federal Advisory Committee Act (Pub. L. 92–463, 86 Stat. 770–776 (5 U.S.C. App. I)), and FDA's regulations (21 CFR Part 14) on advisory committees.

Dated: February 20, 1989.

Frank E. Young,

Commissioner of Food and Drugs.

[FR Doc. 89–4413 Filed 2–24–89; 8:45 am]

BILLING CODE 4160-01-M

Social Security Administration

Privacy Act of 1974; Computer Matching Program

AGENCY: Social Security Administration (SSA), Department of Health and Human Services (HHS).

ACTION: Notice of Computer Matching Program—SSA/Federal Bureau of Prisons (FBP)/State Prison Records—Expansion of the Federal and State Prison Records Matching Program.

SUMMARY: SSA is issuing public notice of its intent to expand the prison records matching program to encompass matching Federal and State prison records with its Privacy Act system of records entitled "Supplemental Security Income Record, HHS/SSA/OSR, 09–60–0103" (hereinafter referred to as the SSR) (last published in the **Federal Register** (FR) at 47 FR 45635, October 13, 1982). State and FBP penal records contain information which may impact on an individual's eligibility for, or amount of, payments under the Supplemental Security Income (SSI) program, title XVI of the Social Security Act (the Act).

Currently, the prison record matching program is an interface between SSA's Master Beneficiary Record (MBR) system of records (last published in the FR at 51 FR 16223, May 1, 1986) and the felony prison files of State and FBP penal institutions. The authority for the current match is section 202(x) of the Act (42 U.S.C. 402(x)) which precludes the payment of Retirement, Survivors, and Disability Insurance benefits under title II of the Act to prisoners who were incarcerated for the commission of felonies. The expanded program will allow for a comparison of the SSR with prison records on felons already obtained for matching with the MBR, and with prison records on nonfelons. The purpose of the expanded program is to detect those cases where incarceration precludes SSI eligibility pursuant to section 1611(e)(1)(A) of the Act (42 U.S.C. 1382(E)(1)(A)) (i.e., the individual was an inmate throughout one or more calendar months).

DATES: Data exchanges involving FBP and State prison records and the MBR have been performed since 1981. Under the expanded program, data exchanges involving these records and the SSR are planned for calendar year 1989 unless we receive comments which result in a contrary determination. Periodic recontacts with the FBP and with State penal institutions may be necessary in the future in order to identify incarcerated individuals.

ADDRESSES: Interested individuals may comment on this notice by writing to the SSA Privacy Officer, Social Security Administration, 3–F–1 Operations Building, 6401 Security Boulevard, Baltimore, Maryland 21235. All comments received will be available for public inspection at this address.

FOR FURTHER INFORMATION CONTACT:

(1) For that portion of the matching program which pertains to the SSR, the appropriate contact is Mr. Gareth Dence, Program Quality Branch, Office of Supplemental Security Income, Social Security Administration, 3–P–1 Operations Building, 6401 Security Boulevard, Baltimore, Maryland 21235, telephone (301) 965–9862.

(2) For that portion of the matching program which pertains to the MBR, the appropriate contact is Mr. William Browne, Special Programs Branch, Office of Disability, Social Security Administration, 3–A–10 Operations Building, 6401 Security Boulevard, Baltimore, Maryland 21235, telephone (301) 965–7685.

(3) For that portion of the matching program which pertains to systems aspects of the match, the appropriate contact is Mr. Charles Martin, Chief, State and Federal Programs Interface Branch, Office of System Requirements, Social Security Administration, 3–Q–11 Operations Building, 6401 Security Boulevard, Baltimore, Maryland 21235, telephone (301) 965–5454.

SUPPLEMENTARY INFORMATION: The current matching program initially resulted from former subsection (f) of section 223 of the Act which precluded

the payment of Social Security title II Disability Insurance benefits to certain prison inmates who are convicted felons. Subsequently, subsection (f) of section 223 was repealed and section 202(x) of the Act was added, precluding persons incarcerated for committing felonies from receiving Retirement and Survivors Insurance benefits as well as Disability Insurance benefits.

We originally reported the Federal and State Prison Records matching program to the Office of Management and Budget (OMB) and Congress on April 14, 1981, as required by the then applicable OMB matching guidance published in the FR on August 4, 1978, and effective on April 4, 1979. The matching program as described at that time consisted of an interface between SSA's MBR and felony prisoner records of the FBP and State penal institutions. We considered the matching program desirable because it insured accurate reporting of incarceration, thereby assisting us in determining whether we are making correct payments of title II benefits.

Our experience with the title II prisoner matching program has shown that incarceration records can be used to determine eligibility for SSI payments. Section 1611(e)(1)(A) of the Act precludes the payment of SSI benefits to any person who is an inmate of a public institution throughout any month. We, therefore, are announcing our intent to match the SSR with FBP and State prisoner records. While the title II prisoner matching program involved only FBP and State felony prisoner records, the proposed expanded matching program involving the SSI records will include matching with nonfelony prisoner records as well. The expanded matching program will help us make timely, proper payment of Retirement, Survivors, and Disability Insurance and SSI payments, and help us prevent and detect erroneous payments.

Further information regarding the prison record matching program, including the authority for the program, a description of the program, the records to be matched, the dates of the program, security safeguards, and plans for disposition of the records are provided in the notice below. This information is required by paragraph 5.f.1 of the Revised Supplemental Guidance for Conducting Computerized Matching Programs (47 FR 21656, May 19, 1982). A copy of the notice has been provided to both Houses of Congress and to OMB.

Dated: February 16, 1989.

Dorcas R. Hardy,

Commissioner of Social Security.

Computer Matching Program

Social Security Administration (SSA) Matching With Federal and State Prison Records—Expansion of Existing Matching Program

A. *Authority.* Sections 202(x), 1611(e)(1)(A), and 1631(f) of the Social Security Act (the Act) (42 U.S.C. 402(x), 1382(e)(1)(A), and 1383(f)).

B. *Description of the Computer Matching Program.*

1. Organizations Involved

SSA, the Federal Bureau of Prisons (FBP), Department of Justice, and State prison systems.

2. Purpose

This matching program resulted from the enactment of former subsection 223(f) of the Act which required SSA to suspend the Disability Insurance benefits payable under title II of the Act to certain beneficiaries who were incarcerated for the commission of felonies.

In April 1983, subsection (f) of section 223 was repealed and subsection (x) was added to section 202 of the Act to provide for suspension of Retirement and Survivors Insurance benefits as well as Disability Insurance benefits payable under title II to incarcerated felons. The matching program was instituted in 1981 and involved matching SSA's Privacy Act system of records entitled "Master Beneficiary Records" (MBR) with FBP and State felony prison records. A notice of the matching program was reported to the Office of Management and Budget (OMB) and the Congress as required by the OMB matching guidelines in effect at that time.

Section 1611(e)(1)(A) of the Act states that all individuals who are inmates of public institutions throughout any month are not eligible for Supplemental Security Income (SSI) payments under title XVI of the Act for that month. To assist us in identifying such individuals, we are expanding the current prison records matching program to allow matching of FBP and State prison records with SSI records which are maintained in our system of records entitled "Supplemental Security Income Record" (SSR).

While the title II matching program involves matching with only felony prisoner records, the expanded matching program involving the SSI records will include matching with nonfelony prisoner records as well. We will request the nonfelony prisoner records from FBP and the States after the expanded matching program becomes effective. The additional matching will serve to detect and/or prevent erroneous SSI payments.

3. *Procedures.* Generally, using the Social Security number (SSN), we will attempt to match each record received from FBP and State prison authorities against the MBR and the SSR systems of records. We will consider a record a nonmatch if the SSNs do not agree. If the SSNs agree, we will use the identifying information in the penal records to ensure that the correct individual is identified on the MBR or SSR before taking any action on payments to the individual.

For those records matched, action will be taken to assure that title II benefits/SSI payments are being paid properly. The FBP and State information matched against the SSR will be treated as a third party lead requiring confirmation prior to proposed payment adjustment. Further development of the case by SSA will be undertaken before any benefits/payments are suspended. We will make no further subsequent contacts with FBP or the States as part of these matches, except in specific cases where issues which arise from the matches must be resolved.

C. *Records to be Matched.* SSA will institute a computerized match of the MBR (last published in the **Federal Register** (FR) at 51 FR 16223, May 1, 1986) and the SSR (last published at 47 FR 45635, October 13, 1982) against identifying information received from the FBP Central Records System, Justice/BOP–005 and State-maintained prison records. The FBP and State records contain information about prisoner incarceration. Included in this information is the prisoner's SSN, name, date of birth, sex, date of confinement, and length of sentence (used to determine felony and nonfelony convictions).

D. *Projected Starting and Ending Dates.* The first matches under the expanded program are scheduled to occur in calendar year 1989. Periodic recontacts with the States and FBP may be necessary in the future in order to identify incarcerated individuals. The cost-effectiveness of the matches under the expanded matching program will determine whether they are continued, expanded, or terminated.

E. *Security Safeguards.* Security safeguards pertaining to the MBR and SSR as reflected in the FR notices (referenced above) for these systems will apply to the matching operation. All magnetic tapes and disks are maintained within an enclosure

attended by security guards. Anyone entering or leaving this enclosure must have a special badge which is issued only to authorized personnel. All microfilm and paper files are accessible only to authorized personnel with a need to know. Safeguards include a lock/unlock password system, exclusive use of leased telephone lines, a terminal-oriented transaction matrix, and an audit trail. The same safeguards will apply to FBP and State tapes while they are in SSA's possession.

F. *Disposition of Records.* Data received from FBP and State prison records will be used only for the purpose of this matching program. The tapes will be returned to these agencies after SSA completes the matching operation. A record of the matches will be placed in the claims folders of selected individuals. Information regarding suspensions of title II benefits and terminations of SSI eligibility will be incorporated into the MBR and the SSR. Printouts of matched records will be disposed of by SSA field office personnel in accordance with the appropriate Federal Records Retention Schedule (44 U.S.C. 3303a).

G. *Other Comments.* For those records matched, SSA will take proper action to assure that Retirement, Survivors, and Disability Insurance and SSI payments are being, made properly. No changes will be made to an individual's payments without providing him/her due process (advance notice of the action to be taken and an opportunity for an appeal after the action is taken).

[FR Doc. 89-4426 Filed 2-24-89; 8:45 am]

BILLING CODE 4190-11-M

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

Office of the Assistant Secretary for Public and Indian Housing

[Docket No. N-89-1934; FR-2611]

Public Housing Program; Demolition or Disposition of Public Housing Projects; Application Submission Deadline; Correction

AGENCY: Office of the Assistant Secretary for Public and Indian Housing, HUD.

ACTION: Notice; correction.

SUMMARY: The purpose of this document is to correct an erroneous application deadline date for the notice regarding the demolition or disposition of public housing projects that was published in the **Federal Register** on February 14, 1989 (54 FR 6772).

FOR FURTHER INFORMATION CONTACT: Janice Rattley, Director, Project Management Division, Office of Public and Housing, Department of Housing and Urban Development, 451 Seventh Street, SW., Washington, DC 20410, telephone, (202) 755-1800. (This is not a toll-free number.)

SUPPLEMENTARY INFORMATION: On February 14, 1989 (54 FR 6772), the Department published a notice announcing the application submission deadline date for PHAs to submit demolition or disposition applications that involved the loss of public housing units and called for assisted housing units to satisfy requirements for a replacement housing plan.

This document corrects an erroneous deadline date that was given in the **SUMMARY** of that notice.

Accordingly, the following correction is made in FR Doc. 89-3395, that appeared in the **Federal Register** on February 14, 1989 (54 FR 6772), as follows:

On page 6772, second column, in the **SUMMARY,** fourth line, correct the date "March 31, 1989" to read "April 14, 1989".

Authority: Sec. 18, U.S. Housing Act of 1937 (42 U.S.C. 1437p); sec. 7(d), Department of Housing and Urban Development Act (42 U.S.C. 3535(d)).

Dated: February 22, 1989.

Grady J. Norris,

Assistant General Counsel for Regulations.

[FR Doc. 89-4482 Filed 2-24-89; 8:45 am]

BILLING CODE 4210-33-M

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[WY-060-09-4920-10-9335, WYW97410 FD and PT]

Proposed Exchange; Schedule for Public Meetings

AGENCY: National Park Service, Interior; Bureau of Land Management, Interior.

ACTION: Notice of public meetings.

SUMMARY: This notice announces the scheduled date and place for public meetings to receive comments on the public interest factors for an exchange involving Federal coal in Sheridan County, Wyoming for a conservation easement within the JY Ranch, a private inholding in the Teton National Park near Jackson, Wyoming.

DATES AND MEETING PLACE: Monday, March 13, 1989, 7:00 p.m., Town Hall Council Chambers, Jackson, WY 83001.

Wednesday, March 15, 1989, 7:00 p.m., Holiday Inn, 1809 Sugarland Drive, Sheridan, WY 82801.

FOR FURTHER INFORMATION CONTACT: All comments and any further information should be addressed to: James W. Monroe, District Manager, Casper District Office, Bureau of Land Management (BLM), 1701 East "E" Street, Casper, Wyoming 82601 (307) 261-5101).

SUPPLEMENTARY INFORMATION: On August 9, 1985 Mr. Laurence S. Rockefeller and Former Secretary of Interior, Donald P. Hodel signed an agreement to pursue an exchange of Federal coal for a conservation easement on Rockefeller's JY Ranch.

In April of 1986, Mr. Rockefeller, the exchange proponent followed with a formal exchange proposal to the Bureau of Land Management which manages the Federal coal reserves.

In December, 1987 Mr. Rockefeller donated this conservation easement to Sloan-Kettering Institute for Cancer Research. The Slone Kettering Institute is the exchange proponent of record.

Specifically, the exchange proposal is a 1,106-acre conservation easement on the JY Ranch in Teton County for approximately 200 million tons of recoverable Federal coal on a 2,500-acre tract referred to as the Young's Creek Exchange Area in Sheridan County, Wyoming. The Young's Creek Exchange Area lies in all or portions of Sections 22, 23, 25, 26, 27, 34 and 35; T. 58 N., R. 84 W., 6th P.M. The conservation easement of the JY Ranch is described by metes and bounds. It is within parts of sections 4, 5, 6 and 8 of T. 42 N., R. 46 W., 6th P.M.

The National Park Service and the Bureau of Land Management are soliciting public comments on the public interest factors of the exchange proposal (BLM Manual 2200.04B) at these scheduled meetings. Comments may be submitted in writing or expressed verbally at the meetings. Comments on these public interest factors for this proposed exchange may also be sent to the Casper District Office, Bureau of Land Management. They must be received in this office no later than March 31, 1989. The specific areas of interest for l;comments are as follows:

(1) What, if any, are the environmental impacts of the proposed exchange?

(2) What are the impacts of the proposed exchange on competitive coal leasing?

(3) Comments or thoughts on public interest involved with processing the proposal.